Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Folia Med (Plovdiv) ; 63(1): 67-73, 2021 Feb 28.
Article in English | MEDLINE | ID: mdl-33650398

ABSTRACT

INTRODUCTION: Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood. Several medicinal plants possess curative and protective effect against thrombocytopenia associated with diseases or drugs. AIM: In the present study, we have investigated the platelet augmentation activity of polyherbal formulation (VITA PLAT Capsule) in cyclophosphamide-induced thrombocytopenic rat model. MATERIALS AND METHODS: Twenty-four albino Wistar rats were divided into four groups. Thrombocytopenia was induced in the rats by administering cyclophosphamide (25 mg/kg, i.p.) for three days to all the groups except normal controls. The test groups were given orally a polyherbal formulation suspended in normal saline for 14 days. Blood was withdrawn from the retro-orbital plexus of the rats on days 1, 7, and 14 of study to determine platelet counts in all groups. Clotting time and bleeding time were determined on the last day of study. Data were collected and analyzed using GraphPad Prism 8. RESULTS: The results showed that the polyherbal formulation treatment could significantly ameliorate platelet count in thrombocyto-penic rats in the initial as well as in the later phase. The total WBC count was also improved during later phase in test groups. However, there is no significant difference between clotting time and bleeding time in all groups. CONCLUSIONS: Our study suggests a potential role of this formulation in the augmentation of platelet counts in various thrombocyto-penic disorders including a role in ameliorating the haemorrhagic complications of dengue fever.


Subject(s)
Blood Platelets/metabolism , Plant Extracts/pharmacology , Plants, Medicinal , Thrombocytopenia/blood , Animals , Blood Platelets/drug effects , Cyclophosphamide/toxicity , Disease Models, Animal , Male , Platelet Count , Rats , Rats, Wistar , Thrombocytopenia/chemically induced , Thrombocytopenia/drug therapy
2.
Folia Med (Plovdiv) ; 63(5): 775-785, 2021 Oct 31.
Article in English | MEDLINE | ID: mdl-35851213

ABSTRACT

INTRODUCTION: Nanoparticle formulation of pitavastatin calcium is a potential alternative to solve the solubility related problem. However, the formulation of nanoparticle involves various parameters that affect product quality. Plackett-Burman design could facilitate an economical experimental plan that focuses on determining the relative significance of many. AIM: The objective of this study was to screen the variables which could significantly affect the pitavastatin nanoparticle formulation. MATERIALS AND METHODS: The pitavastatin nanoparticles were formulated by preparing nanosuspension using the emulsion solvent evaporation technique followed by freeze-drying. A Plackett-Burman screening design methodology was employed in which seven factors at two levels were tested at 12 runs to study the effect of formulation and process variables on particle size and polydispersity index of nanoparticles. The surface morphology and crystalline nature of nanoparticle were also evaluated. RESULTS: The particle size and polydispersity index of nanosuspension was found in the range of 113.1 to 768.5 nm and 0.068 to 0.508, respectively. Statistical analysis of various variables revealed that stabilizer concentration, injection flow rate, and stirring rate were the most influential factors affecting the particle size and polydispersity index of the formulation. X-ray diffraction (XRD) and scanning electron microscopy (SEM) study suggested the amorphous nature of nanoparticles. CONCLUSIONS: This study concluded that the Plackett-Burman design was an efficient tool for screening the process and formulation variables affecting the properties of pitavastatin nanoparticles and also for the identification of the most prominent factor.


Subject(s)
Nanoparticles , Quinolines , Particle Size , Solubility
3.
Curr Drug Res Rev ; 12(2): 175-182, 2020.
Article in English | MEDLINE | ID: mdl-32077837

ABSTRACT

BACKGROUND: Despite many successes in the discovery of numerous cancer chemotherapeutic agents from natural sources, some of the moieties were dropped because of its inefficiency or serious toxicity. Mitosis is an ordered series of fundamentally mechanical events in which identical copies of the genome are moved to two discrete locations within the dividing cell. The crucial role of the mitotic spindle in cell division has identified, which is an important target in cancer chemotherapy. In the present study, we are reporting molecular docking studies and in silico pharmacokinetic profiles of selected phytoconstituents obtained from Amyris pinnata. METHODS: Molecular docking studies of selected phytoconstituents were performed using iGEMDOCK. The crystal structure of the protein was exported from the protein data bank (PDB id: 4C4H). In silico pharmacokinetic profile of selected phytoconstituents was performed using the SWISSADME server. RESULTS: Compound AMNP6 showed higher binding affinity as compared to the standard ligand. All the selected phytoconstituents have passed the Lipinski rule of five and shown no violations. CONCLUSION: Good binding affinity and drug likeliness of the AMNP6 suggest that it can be further investigated and explored as mitotic spindle kinase inhibitor in cancer disease.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Plant Extracts/pharmacology , Protein Kinase Inhibitors/pharmacology , Rutaceae/chemistry , Antineoplastic Agents, Phytogenic/isolation & purification , Antineoplastic Agents, Phytogenic/pharmacokinetics , Computer Simulation , Drug Discovery , Humans , Molecular Docking Simulation , Plant Extracts/pharmacokinetics , Protein Kinase Inhibitors/isolation & purification , Protein Kinase Inhibitors/pharmacokinetics , Spindle Apparatus/metabolism
4.
Folia Med (Plovdiv) ; 61(4): 584-593, 2019 12 31.
Article in English | MEDLINE | ID: mdl-32337872

ABSTRACT

BACKGROUND: Aspartic protease found in plasmodium parasites such as plasmepsin I, II and IV plays an important role in the degradation of hemoglobin. The studies have shown that effective drug must be able to inhibit more than one type of plasmepsin to avoid further growth of parasites and to prevent resistance of drug. Therefore, plasmepsins are believed to be excellent drug target for malarial disease. Extract of the plant Euphorbia hirta has been proved to exert antimalarial activity. However, molecular mechanism of this activity was not described. AIM: The aim of present investigation is to identify antimalarial phytochemicals of Euphorbia hirta as plasmepsin protease inhibitors using an in silico approach. MATERIALS AND METHODS: Docking studies were performed on three different protein targets plasmepsin I, II, and IV using iGEMDOCK. ADME and bioactivity predictions were done using molinspiration online tool. Toxicity studies were performed using ProTox-II online tool. RESULTS: In the docking studies seven compounds showed significant inhibitory activity with low docking score as compared to standard drug artemisinin. Six compounds showed no violations as per Lipinski rule. Bioactivity prediction states that all the compounds may act through enzyme inhibition. The results of in silico studies suggest that out of the eleven selected phytochemicals isorhamnetin and pinocembrin have more drug likeliness properties and lesser in silico toxicity with more binding affinity than artemisinin on all receptors. CONCLUSION: These findings indicate that isorhamnetin and pinocembrin have promising potential for development of antimalarial drug as plasmepsin inhibitors.


Subject(s)
Antimalarials/pharmacology , Aspartic Acid Endopeptidases/antagonists & inhibitors , Euphorbia/chemistry , Phytochemicals/pharmacology , Protease Inhibitors/pharmacology , Drug Development , Molecular Docking Simulation , Phytochemicals/chemistry
5.
Drug Dev Ind Pharm ; 44(4): 687-696, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29168671

ABSTRACT

The objective of this work was to utilize a potential of microemulsion for the improvement in oral bioavailability of raloxifene hydrochloride, a BCS class-II drug with 2% bioavailability. Drug-loaded microemulsion was prepared by water titration method using Capmul MCM C8, Tween 20, and Polyethylene glycol 400 as oil, surfactant, and co-surfactant respectively. The pseudo-ternary phase diagram was constructed between oil and surfactants mixture to obtain appropriate components and their concentration ranges that result in large existence area of microemulsion. D-optimal mixture design was utilized as a statistical tool for optimization of microemulsion considering oil, Smix, and water as independent variables with percentage transmittance and globule size as dependent variables. The optimized formulation showed 100 ± 0.1% transmittance and 17.85 ± 2.78 nm globule size which was identically equal with the predicted values of dependent variables given by the design expert software. The optimized microemulsion showed pronounced enhancement in release rate compared to plain drug suspension following diffusion controlled release mechanism by the Higuchi model. The formulation showed zeta potential of value -5.88 ± 1.14 mV that imparts good stability to drug loaded microemulsion dispersion. Surface morphology study with transmission electron microscope showed discrete spherical nano sized globules with smooth surface. In-vivo pharmacokinetic study of optimized microemulsion formulation in Wistar rats showed 4.29-fold enhancements in bioavailability. Stability study showed adequate results for various parameters checked up to six months. These results reveal the potential of microemulsion for significant improvement in oral bioavailability of poorly soluble raloxifene hydrochloride.


Subject(s)
Raloxifene Hydrochloride/administration & dosage , Raloxifene Hydrochloride/pharmacokinetics , Selective Estrogen Receptor Modulators/administration & dosage , Selective Estrogen Receptor Modulators/pharmacokinetics , Animals , Biological Availability , Delayed-Action Preparations , Drug Compounding , Drug Delivery Systems , Drug Stability , Emulsions , Excipients , Particle Size , Raloxifene Hydrochloride/chemistry , Rats , Rats, Wistar , Selective Estrogen Receptor Modulators/chemistry , Solubility , Surface-Active Agents , Viscosity
6.
Indian J Pharmacol ; 47(1): 17-21, 2015.
Article in English | MEDLINE | ID: mdl-25821305

ABSTRACT

OBJECTIVE: Statins have anti-inflammatory effects that are not directly related to their cholesterol lowering activity. This study was carried out to evaluate the effect of simvastatin or rosuvastatin on the extent of colonic mucosal damage and on the inflammatory response in trinitrobenzene sulfonic acid (TNBS)-induced ulcerative colitis. MATERIALS AND METHODS: Ulcerative colitis was induced by single intrarectal injection of 120 mg/kg TNBS. Test groups were treated with simvastatin (10 mg/kg, p.o.) or rosuvastatin (10 mg/kg, p.o.). Colonic mucosal inflammation was evaluated clinically, biochemically, and histologically. RESULT: Disease activity index score in TNBS-treated rats, as determined by weight loss, stool consistency, fecal occult blood, were significantly lowers in simvastatin or rosuvastatin-treated rats than TNBS-treated animals. Simvastatin or rosuvastatin counteracted the reduction in colon length, decreased colon weight, neutrophil accumulation, and tumor necrosis factor-alpha level in TNBS-induced colitis. Simvastatin and rosuvastatin also inhibited the increase in oxidative stress levels after TNBS administration. CONCLUSIONS: These results suggest that simvastatin and rosuvastatin significantly ameliorate experimental colitis in rats, and these effects could be explained by their anti-inflammatory and antioxidant activity.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Antioxidants/pharmacology , Colitis, Ulcerative/prevention & control , Colon/drug effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Rosuvastatin Calcium/pharmacology , Simvastatin/pharmacology , Trinitrobenzenesulfonic Acid , Animals , Colitis, Ulcerative/chemically induced , Colitis, Ulcerative/metabolism , Colitis, Ulcerative/pathology , Colon/metabolism , Colon/pathology , Cytoprotection , Disease Models, Animal , Female , Glutathione/metabolism , Inflammation Mediators/metabolism , Malondialdehyde/metabolism , Neutrophil Infiltration/drug effects , Oxidative Stress/drug effects , Peroxidase/metabolism , Rats, Wistar , Superoxide Dismutase/metabolism , Tumor Necrosis Factor-alpha/metabolism
7.
Indian J Pharmacol ; 45(4): 354-8, 2013.
Article in English | MEDLINE | ID: mdl-24014910

ABSTRACT

OBJECTIVES: This study aimed to investigate the protective effect of simvastatin (SIM) and rosuvastatin (RST) on cisplatin (CIS)-induced nephrotoxicity. MATERIALS AND METHODS: Adult female Wistar rats were divided into six groups: control group (Group 1) received 0.5% sodium carboxy methyl cellulose, group 2 and group 3 received SIM and RST for 10 days, respectively, and group 4 was injected single dose of CIS (7 mg/kg, i.p.). Group 5 and 6 were treated with SIM (10 mg/kg, p.o.) and RST (10 mg/kg, p.o.) for 10 days, respectively. All groups received cisplatin on the 5(th) day of treatment. Renal function tests like serum creatinine, urea, BUN, albumin, calcium, uric acid and magnesium, serum lipids, and markers of oxidative stress such as renal malondialdehyde (MDA) level and superoxide dismutase (SOD) and catalase (CAT) activities were measured. All tissues were investigated for histopathological changes. RESULT: CIS reduced the renal function, which was reflected with significant increase in serum urea, BUN, serum creatinine, uric acid and also significant decrease serum calcium, magnesium, albumin levels. In addition, cisplatin caused renal tubular damage with a higher MDA level, depletion of SOD and CAT activity, and elevation of serum lipids. SIM or RST ameliorate CIS induced renal damage due to improvement in renal function, oxidative stress, suppression of serum lipids, and histological alteration. CONCLUSIONS: This finding suggests that simvastatin and rosuvastatin may have a protective effect against cisplatin-induced kidney damage via amelioration of lipid peroxidation as well as due to improvement of renal function, and lipid-lowering effects.


Subject(s)
Fluorobenzenes/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Kidney Diseases/drug therapy , Protective Agents/administration & dosage , Pyrimidines/administration & dosage , Simvastatin/administration & dosage , Sulfonamides/administration & dosage , Animals , Blood Urea Nitrogen , Calcium/blood , Catalase/metabolism , Cholesterol/blood , Cisplatin , Creatinine/blood , Drug Therapy, Combination , Female , Kidney/drug effects , Kidney/metabolism , Kidney/pathology , Kidney Diseases/chemically induced , Kidney Diseases/metabolism , Kidney Diseases/pathology , Magnesium/blood , Malondialdehyde/metabolism , Rats , Rats, Wistar , Rosuvastatin Calcium , Serum Albumin/analysis , Superoxide Dismutase/metabolism , Triglycerides/blood , Urea/blood , Uric Acid/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...